Mirum Pharmaceuticals, Inc. (MIRM) Misses Q2 EPS by 122c

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($1.94), $1.22 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $37.5 million versus the consensus estimate of $30.23 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Aspire Biopharma to acquire automotive supplier for $30 million
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c